BACARDI
12.9.2022 13:01:51 CEST | Business Wire | Press release
Bacardi announces a change at the top of its global travel retail business (GTR), effective January 2023. The current Managing Director, Vinay Golikeri, moves out of global travel retail to take on the role of Managing Director, India, and Neighboring Countries, handing over the reins to Leila Stansfield. Leila is an experienced global travel retail veteran, having previously held roles as GTR Finance Director and GTR Marketing Director. She will be the first female lead for the division. She is currently On-Trade Sales Director, Bacardi UK & Ireland.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220912005141/en/
Leila Stansfield to lead Bacardi global travel retail business (GTR), effective January 2023. (Photo: Business Wire)
Vijay Subramaniam, Regional President AMEA & GTR, Bacardi comments on the change, “Vinay has played a pivotal role in leading and developing our global travel retail business. The last few years have been particularly difficult for this channel, and Vinay has successfully navigated the challenges of the pandemic. He has spearheaded our ambitions as a front-runner in the omnichannel revolution sweeping travel retail by partnering with retail customers, introducing significant innovation in shopper experience and our brand portfolio. I would like to thank Vinay for his unwavering drive and positive leadership and to wish him every success in his new role.
“Meanwhile, we are delighted to welcome Leila Stansfield back to GTR. She is a driving force in our senior leadership team and brings valuable commercial acumen from across several aspects of our business. This is a time of transformational opportunity for global travel retail and Bacardi is deeply committed for the long term. With a passion for people – our customers, consumers and for unlocking potential in her team - Leila will be a tremendous leader to move GTR into the new omnichannel era, maximizing the unrivaled dynamics in terms of strategic brand-building and commercial opportunity as well as driving our ESG goals – a key objective in our strategic ambitions for global travel retail.”
Commenting on his time in Bacardi GTR, Vinay Golikeri said, “It’s been such a privilege to lead the Bacardi global travel retail business, and I would especially like to call out the most magnificent team of talented people I’ve worked with and to thank them for their fearless commitment and passion. These individuals have delivered phenomenal work in the toughest of times, enabling us to reinvent our business in global travel retail and to emerge stronger with new possibilities, notably in forging omnichannel solutions that are the bedrock of the new era in this remarkable market.”
Looking ahead to her new role, Leila Stansfield adds, “I am very excited to be returning to global travel retail in January 2023, especially at a time when the market looks set to move towards full recovery. I look forward to reconnecting with our retail partners and stakeholders to accelerate and deliver mutually beneficial strategies for growth.”
NOTES TO EDITORS
About BACARDI GLOBAL TRAVEL RETAIL
The Bacardi Global Travel Retail Division is a stand-alone business unit of Bacardi Limited. Through Bacardi’s portfolio of premium and super-premium brands, including BACARDÍ® rum, GREY GOOSE® vodka, DEWAR’S® blended Scotch whisky, BOMBAY SAPPHIRE® gin, PATRÓN® tequila, MARTINI® vermouth and sparkling wine, SAINT GERMAIN® liqueur, BARON OTARD® cognac, BÉNÉDICTINE® liqueur, and 42BELOW® vodka, the Bacardi Global Travel Retail Division creates unique and innovative experiences for travelers.
The brands noted above are part of the portfolio of Bacardi Limited, headquartered in Hamilton, Bermuda. Bacardi Limited refers to the Bacardi group of companies, including Bacardi International Limited. Drink Responsibly
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005141/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 21:25:00 CEST | Press release
Alsym’s proprietary physics-informed AI platform powered the development of its Na-Series batteries—a non-flammable, high performance and low cost energy solution positioned to serve critical energy storage markets including data centers, utilities, telecommunications, commercial real estate, industrial and defense, among others. Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Li
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 16:00:00 CEST | Press release
As pharma manufacturers prioritize US supply chain resilience, highlights include high-speed isolator filling lines for prefilled syringes, cartridges and vials, and drug-device combination assembly and packaging. PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpi
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 15:53:00 CEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Taiho Oncology, Taiho Pharmaceutical and Araris Biotech AG Advance ADC ARC-02 into Phase 1 Clinical Development27.4.2026 15:00:00 CEST | Press release
Phase 1 dose-escalation trial represents the first clinical trial of a product developed using the AraLinQ™ ADC technology and marks Taiho’s expansion into the clinical development of ADCs for oncology Taiho Oncology, Inc., Taiho Pharmaceutical Co., Ltd., and Araris Biotech AG (“Araris”) today announced that the U.S. Food and Drug Administration (FDA) has completed its Investigational New Drug (IND) review period for ARC-02, an antibody-drug conjugate (ADC) being developed for the treatment of non-Hodgkin lymphoma, enabling Taiho Oncology to initiate a Phase 1 dose-escalation clinical trial of ARC-02. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427127507/en/ Taiho Pharmaceutical acquired Araris Biotech in March 2025, expanding Taiho group’s capabilities in biologics and ADC research and development. Araris is a spin-off of the Paul Scherrer Institute and ETH in Switzerland focused on the development of antibody-drug co
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 15:00:00 CEST | Press release
Premier global event to highlight how organizations are bringing data to life to power everything from AI to BI Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
